CD20 Level
OVERVIEW EXPLANATION
The CD20 protein is produced by members of the B family of Immune Cells. CD20 protein can also be found within the bloodstream. Its levels are substantially increased on most B cells that have become malignant. Hence, an assay that detects elevated levels of cellular CD20 suggests the presence of cancerous B cells. The absence of CD20 in either cellular or blood-soluble form reveals that there is no development of cancerous B cells.
DETAILED EXPLANATION
The CD20 Antigen is a transmembrane protein. Normally it is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. CD20 is in low density on all normal B lymphocytes from peripheral blood, lymph node, spleen, tonsil and bone marrow but is absent from plasma cells. The CD20 Antigen expression is significantly increased on most malignant B cells. In some instances, the soluble CD20 Antigen can be detected in the blood stream. This indicates the destruction through the apoptotic process of B cells, probably in the main abnormal or malignant cells. This assay is able to provide information relating to the presence of abnormal, including malignant B cells and also their destruction.
Any increased levels of cellular CD20 are associated with the presence of abnormal, presumably malignant, B cells, whilst any increased levels of soluble CD20 indicate their destruction. The absence of any levels of both cellular CD20 and soluble CD20 of their trace indicates the absence of malignant B cells. The absence of any levels of cellular CD20, whilst there are increased levels of soluble CD20, indicates that there is formation of malignant B cells followed by their total destruction.
APPLICATION
This assay will provide extremely valuable and accurate information relating to all forms of cancer.
The CD20 protein is produced by members of the B family of Immune Cells. CD20 protein can also be found within the bloodstream. Its levels are substantially increased on most B cells that have become malignant. Hence, an assay that detects elevated levels of cellular CD20 suggests the presence of cancerous B cells. The absence of CD20 in either cellular or blood-soluble form reveals that there is no development of cancerous B cells.
DETAILED EXPLANATION
The CD20 Antigen is a transmembrane protein. Normally it is expressed on B lineage cells from the pre-B cell stage to the B cell lymphoblast stage. CD20 is in low density on all normal B lymphocytes from peripheral blood, lymph node, spleen, tonsil and bone marrow but is absent from plasma cells. The CD20 Antigen expression is significantly increased on most malignant B cells. In some instances, the soluble CD20 Antigen can be detected in the blood stream. This indicates the destruction through the apoptotic process of B cells, probably in the main abnormal or malignant cells. This assay is able to provide information relating to the presence of abnormal, including malignant B cells and also their destruction.
Any increased levels of cellular CD20 are associated with the presence of abnormal, presumably malignant, B cells, whilst any increased levels of soluble CD20 indicate their destruction. The absence of any levels of both cellular CD20 and soluble CD20 of their trace indicates the absence of malignant B cells. The absence of any levels of cellular CD20, whilst there are increased levels of soluble CD20, indicates that there is formation of malignant B cells followed by their total destruction.
APPLICATION
This assay will provide extremely valuable and accurate information relating to all forms of cancer.